The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
7.94 crore doses were made available to the states in May 2021
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Subscribe To Our Newsletter & Stay Updated
